Ruth M. Stone - Publications

Affiliations: 
Anthropology Indiana University, Bloomington, Bloomington, IN, United States 
Area:
Cultural Anthropology, Music, Native American Studies, General Religion

214 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Tanasijevic AM, Revette A, Klepin HD, Zeidan A, Townsley D, DiNardo CD, Sebert M, DeZern AE, Stone RM, Magnavita ES, Chen R, Sekeres MA, Abel GA. Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. Leukemia & Lymphoma. 1-5. PMID 32667230 DOI: 10.1080/10428194.2020.1791854  0.36
2019 Slavin SD, Fenech A, Jankowski AL, Abel GA, Brunner AM, Steensma DP, Fathi AT, DeAngelo DJ, Wadleigh M, Hobbs GS, Amrein PC, Stone RM, Temel JS, El-Jawahri A. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. PMID 31299106 DOI: 10.1002/cncr.32397  0.36
2019 Liu MA, DuMontier C, Murillo A, Hshieh T, Bean JF, Soiffer RJ, Stone RM, Abel GA, Driver JA. Gait speed, grip strength and clinical outcomes in older patients with hematologic malignancies. Blood. PMID 31167800 DOI: 10.1182/blood.2019000758  0.36
2019 DuMontier C, Liu MA, Murillo A, Hshieh T, Javedan H, Soiffer R, Stone RM, Driver JA, Abel GA. Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies. Journal of the American Geriatrics Society. PMID 30945759 DOI: 10.1111/jgs.15835  0.36
2019 El-Jawahri A, Abel GA, Traeger L, Waldman L, Markovitz N, VanDusen H, Fathi A, Steensma DP, LeBlanc TW, Horick NK, DeAngelo DJ, Wadleigh M, Hobbs G, Foster J, Brunner AM, ... ... Stone RM, et al. Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. PMID 30923318 DOI: 10.1038/s41375-019-0449-1  0.36
2018 Stone RM, Lindsley C. Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply. Haematologica. 103: 1758-1759. PMID 30381416 DOI: 10.3324/haematol.2018.201848  0.32
2018 El-Jawahri A, Nelson-Lowe M, VanDusen H, Traeger L, Abel GA, Greer JA, Fathi A, Steensma DP, LeBlanc TW, Li Z, DeAngelo D, Wadleigh M, Hobbs G, Foster J, Brunner A, ... ... Stone RM, et al. Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. The Oncologist. PMID 30139841 DOI: 10.1634/theoncologist.2018-0317  0.36
2018 Brunner AM, Weng S, Cronin A, Fathi AT, Habib AR, Stone R, Graubert T, Steensma DP, Abel GA. Impact of Lenalidomide Use among Non-Transfusion Dependent Patients with Myelodysplastic Syndromes. American Journal of Hematology. PMID 30033577 DOI: 10.1002/ajh.25166  0.36
2018 Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP, Chen YA, Fathi AT, Graubert TA, Brunner AM, Wadleigh M, Stone RM, DeAngelo DJ, Nardi V, Hasserjian RP, et al. High NPM1 mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. PMID 29724895 DOI: 10.1182/blood-2018-01-828467  0.36
2018 Hshieh TT, Jung WF, Grande LJ, Chen J, Stone RM, Soiffer RJ, Driver JA, Abel GA. Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. Jama Oncology. PMID 29494732 DOI: 10.1001/jamaoncol.2017.5674  0.36
2017 Luskin MR, Cronin AM, Owens RL, DeAngelo DJ, Stone RM, Wadleigh M, Steensma DP, Abel GA. Self-reported sleep disturbance and survival in myelodysplastic syndromes. British Journal of Haematology. PMID 28272741 DOI: 10.1111/bjh.14573  0.36
2016 Xiang M, Kim H, Ho VT, Walker SR, Bar-Natan M, Anahtar M, Liu S, Toniolo PA, Kroll Y, Jones N, Giaccone ZT, Heppler LN, Ye DQ, Marineau JJ, Shaw D, ... ... Stone RM, et al. Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anti-cancer agent. Blood. PMID 27531676 DOI: 10.1182/blood-2015-07-660506  0.36
2016 Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, ... ... Stone RM, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 30: 183. PMID 27479034 DOI: 10.1016/j.ccell.2016.06.008  0.36
2016 Liu X, Wang A, Liang X, Liu J, Zou F, Chen C, Zhao Z, Deng Y, Wu H, Qi Z, Wang B, Wang L, Liu F, Xu Y, Wang W, ... ... Stone RM, et al. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies. Oncotarget. PMID 27447747 DOI: 10.18632/oncotarget.10650  0.44
2016 Eisfeld AK, Kohlschmidt J, Mrózek K, Blachly JS, Nicolet D, Kroll K, Orwick S, Carroll AJ, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD. Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2. Leukemia. PMID 27435003 DOI: 10.1038/leu.2016.196  0.44
2016 Brunner AM, Li S, Fathi AT, Wadleigh M, Ho VT, Collier K, Connolly C, Ballen KK, Cutler CS, Dey BR, El-Jawahri A, Nikiforow S, McAfee SL, Koreth J, Deangelo DJ, ... ... Stone RM, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. British Journal of Haematology. PMID 27434660 DOI: 10.1111/bjh.14260  0.36
2016 Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, et al. Targeting MTHFD2 in acute myeloid leukemia. The Journal of Experimental Medicine. PMID 27325891 DOI: 10.1084/jem.20151574  0.44
2016 El-Jawahri A, Keenan T, Abel GA, Steensma DP, LeBlanc TW, Chen YB, Hobbs G, Traeger L, Fathi AT, DeAngelo DJ, Wadleigh M, Ballen KK, Amrein PC, Stone RM, Temel JS. Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. The Lancet. Haematology. 3: e276-e283. PMID 27264037 DOI: 10.1016/S2352-3026(16)30024-2  0.44
2016 Wu H, Wang A, Qi Z, Li X, Chen C, Yu K, Zou F, Hu C, Wang W, Zhao Z, Wu J, Liu J, Liu X, Wang L, Wang W, ... ... Stone RM, et al. Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia. PMID 27220667 DOI: 10.1038/leu.2016.151  0.44
2016 Hatcher JM, Weisberg E, Sim T, Stone RM, Liu S, Griffin JD, Gray NS. Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. Acs Medicinal Chemistry Letters. 7: 476-81. PMID 27190596 DOI: 10.1021/acsmedchemlett.5b00498  0.44
2016 Fathi AT, DeAngelo DJ, Stevenson KE, Kolitz JE, Asch JD, Amrein PC, Attar EC, Steensma DP, Wadleigh M, Foster J, Connolly C, Galinsky I, Devoe CE, Stone RM, Neuberg DS, et al. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. PMID 27171984 DOI: 10.1002/cncr.30037  0.44
2016 Wolach O, Stevenson KE, Wadleigh M, DeAngelo DJ, Steensma DP, Ballen KK, Soiffer RJ, Antin JH, Neuberg DS, Ho VT, Stone RM. Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. American Journal of Hematology. PMID 27153389 DOI: 10.1002/ajh.24410  0.44
2016 Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Deininger MW, Bradley-Garelik MB, Mohamed H, Guilhot F. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia. PMID 27133948 DOI: 10.1016/j.clml.2016.03.004  0.44
2016 Stone RM. Transplantation after Remission in Mixed Phenotype Acute Leukemia: A Good Idea. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 22: 971-972. PMID 27095690 DOI: 10.1016/j.bbmt.2016.04.001  0.44
2016 Liu X, Wang A, Liang X, Chen C, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, Adamia S, Stone RM, et al. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. PMID 27081697 DOI: 10.18632/oncotarget.8702  0.44
2016 Wang A, Wu H, Chen C, Hu C, Qi Z, Wang W, Yu K, Liu X, Zou F, Zhao Z, Wu J, Liu J, Liu F, Wang L, Stone RM, et al. Dual Inhibition of AKT/FLT3-ITD by A674563 Overcomes FLT3 Ligand-Induced Drug Resistance in FLT3-ITD positive AML. Oncotarget. PMID 27074558 DOI: 10.18632/oncotarget.8675  0.44
2016 Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, ... ... Stone RM, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 29: 574-86. PMID 27070704 DOI: 10.1016/j.ccell.2016.03.008  0.36
2016 Rashidi A, Wolach O, El-Jawahri A, Ho VT, DiPersio JF, Soiffer R, Stone RM, Chen YB. The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. Leukemia & Lymphoma. 1-3. PMID 27003236 DOI: 10.3109/10428194.2016.1161188  0.44
2016 El-Jawahri A, Kim HT, Steensma DP, Cronin AM, Stone RM, Watts CD, Chen YB, Cutler CS, Soiffer RJ, Abel GA. Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transplantation. PMID 26999469 DOI: 10.1038/bmt.2016.40  0.44
2016 Abel GA, Cronin AM, Odejide OO, Uno H, Stone RM, Steensma DP. Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes. British Journal of Haematology. PMID 26913376 DOI: 10.1111/bjh.13987  0.44
2016 DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan CG, Stock W. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leukemia & Lymphoma. 1-9. PMID 26892479 DOI: 10.3109/10428194.2016.1144881  0.44
2015 Keenan T, Abel GA, Steensma DP, LeBlanc TW, Traeger L, Fathi AT, DeAngelo DJ, Wadleigh M, Hobbs G, Amrein PC, Stone RM, Ballen KK, Chen YA, Temel JS. Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 206. PMID 28148109 DOI: 10.1200/jco.2015.33.29_suppl.206  0.36
2015 Cronin A, Watts CD, Steensma DP, Stone RM, DeAngelo DJ, Owens RL, Wadleigh M, Abel GA. Impact of sleep disturbance in myelodysplastic syndromes (MDS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 99. PMID 28148038 DOI: 10.1200/jco.2015.33.29_suppl.99  0.36
2015 Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, et al. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26527780 DOI: 10.1200/JCO.2015.62.7273  0.44
2015 Castillo JJ, Mulkey F, Geyer S, Kolitz JE, Blum W, Powell BL, George SL, Larson RA, Stone RM. Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (Alliance) clinical trials. American Journal of Hematology. PMID 26526191 DOI: 10.1002/ajh.24230  0.44
2015 Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, Thiele J, Rodig S, Pozdnyakova O. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. Journal of Translational Medicine. 13: 294. PMID 26357842 DOI: 10.1186/s12967-015-0644-4  0.44
2015 Ustun C, Stone R, Weisdorf D. New Models of Therapy: When Acute Leukemia Becomes Chronic. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 1856-7. PMID 26183079 DOI: 10.1016/j.bbmt.2015.07.011  0.44
2015 Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, ... ... Stone RM, et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 28: 29-41. PMID 26175414 DOI: 10.1016/j.ccell.2015.06.005  0.44
2015 Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, ... ... Stone RM, et al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. PMID 26165234 DOI: 10.1038/leu.2015.180  0.44
2015 Fega KR, Abel GA, Motyckova G, Sherman AE, DeAngelo DJ, Steensma DP, Galinsky I, Wadleigh M, Stone RM, Driver JA. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. Journal of Geriatric Oncology. PMID 26073533 DOI: 10.1016/j.jgo.2015.05.003  0.44
2015 El-Jawahri AR, Abel GA, Steensma DP, LeBlanc TW, Fathi AT, Graubert TA, DeAngelo DJ, Wadleigh M, Ballen KK, Foster JE, Attar EC, Amrein PC, Brunner AM, Stone RM, Temel JS. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. PMID 25926135 DOI: 10.1002/cncr.29430  0.44
2015 Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, et al. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1252-7. PMID 25732165 DOI: 10.1200/JCO.2014.57.0952  0.44
2015 Wolach O, Stone RM. How I treat mixed-phenotype acute leukemia Blood. 125: 2477-2485. PMID 25605373 DOI: 10.1182/blood-2014-10-551465  0.44
2015 Wolach O, Stone RM. Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1? Current Opinion in Hematology. 22: 123-131. PMID 25594168 DOI: 10.1097/MOH.0000000000000119  0.44
2015 Roberts DA, Wadleigh M, McDonnell AM, DeAngelo DJ, Stone RM, Steensma DP. Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Leukemia Research. 39: 204-10. PMID 25554239 DOI: 10.1016/j.leukres.2014.11.031  0.44
2015 Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, ... ... Stone RM, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 125: 1367-76. PMID 25550361 DOI: 10.1182/blood-2014-11-610543  0.44
2015 Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, et al. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. British Journal of Haematology. 168: 796-805. PMID 25403830 DOI: 10.1111/bjh.13214  0.44
2015 Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, ... ... Stone RM, et al. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 29: 567-75. PMID 25204569 DOI: 10.1038/leu.2014.267  0.44
2015 DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, ... ... Stone RM, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 29: 526-34. PMID 25079173 DOI: 10.1038/leu.2014.229  0.44
2015 Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Martinelli G, ... ... Stone RM, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts Blood. 126: 291-299. DOI: 10.1182/blood-2015-01-621664  0.44
2015 Wolach O, Stone RM. Blinatumomab for the treatment of Philadelphia chromosome-negative, precursor B-cell acute lymphoblastic leukemia Clinical Cancer Research. 21: 4262-4269. DOI: 10.1158/1078-0432.CCR-15-0125  0.44
2015 Weinberg OK, Pozdnyakova O, Campigotto F, Deangelo DJ, Stone RM, Neuberg D, Hasserjian RP. Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia Modern Pathology. 28: 965-976. DOI: 10.1038/modpathol.2015.55  0.44
2015 Stone RM. Should older adults with AML receive post-remission therapy? Best Practice and Research: Clinical Haematology. 28: 106-111. DOI: 10.1016/j.beha.2015.10.007  0.44
2015 Motyckova G, Stone RM. Development of midostaurin as a tyrosine kinase inhibitor Targeted Therapy of Acute Myeloid Leukemi. 201-214. DOI: 10.1007/978-1-4939-1393-0_10  0.44
2014 Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, ... ... Stone RM, et al. Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 111: 18679-84. PMID 25512507 DOI: 10.1073/pnas.1422050112  0.44
2014 Graubert T, Stone R. AML Genomics for the Clinician Seminars in Hematology. 51: 322-329. PMID 25311744 DOI: 10.1053/j.seminhematol.2014.08.006  0.44
2014 Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 124: 2705-12. PMID 25224413 DOI: 10.1182/blood-2014-06-582809  0.44
2014 Hasserjian RP, Campigotto F, Klepeis V, Fu B, Wang SA, Bueso-Ramos C, Cascio MJ, Rogers HJ, Hsi ED, Soderquist C, Bagg A, Yan J, Ochs R, Orazi A, Moore F, ... ... Stone RM, et al. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study. American Journal of Hematology. 89: E193-9. PMID 25042343 DOI: 10.1002/ajh.23808  0.44
2014 Becker H, Maharry K, Mrózek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D, Paschka P, Powell BL, ... ... Stone RM, et al. Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia. 28: 1754-8. PMID 24651097 DOI: 10.1038/leu.2014.114  0.44
2014 Steensma DP, Komrokji RS, Stone RM, List AF, Garcia-Manero G, Huber JM, Dennison B, Sekeres MA. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 120: 1670-6. PMID 24577838 DOI: 10.1002/cncr.28631  0.44
2014 Adamia S, Bar-Natan M, Haibe-Kains B, Pilarski PM, Bach C, Pevzner S, Calimeri T, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, ... ... Stone RM, et al. NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood. 123: 2816-25. PMID 24574459 DOI: 10.1182/blood-2013-02-481507  0.44
2014 Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, DeAngelo DJ, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 25: 226-42. PMID 24525236 DOI: 10.1016/j.ccr.2014.01.022  0.44
2014 Deangelo DJ, Neuberg D, Amrein PC, Berchuck J, Wadleigh M, Sirulnik LA, Galinsky I, Golub T, Stegmaier K, Stone RM. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leukemia Research. 38: 430-4. PMID 24522247 DOI: 10.1016/j.leukres.2013.10.026  0.44
2014 Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrózek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, ... ... Stone RM, et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 548-56. PMID 24378410 DOI: 10.1200/JCO.2013.50.6337  0.44
2014 Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, Kaur S, Wang S, Chen Y, Wu A, Shen M, Gibbons FD, Lamb ML, Zheng X, Stone RM, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 123: 905-13. PMID 24363397 DOI: 10.1182/blood-2013-04-495366  0.44
2014 Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, ... ... Stone RM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discovery. 4: 362-75. PMID 24346116 DOI: 10.1158/2159-8290.CD-13-0609  0.44
2014 Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrózek K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, ... ... Stone RM, et al. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 28: 1252-8. PMID 24326683 DOI: 10.1038/leu.2013.371  0.44
2014 Adamia S, Haibe-Kains B, Pilarski PM, Bar-Natan M, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Burke J, Galinsky I, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, ... ... Stone R, et al. A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1135-45. PMID 24284058 DOI: 10.1158/1078-0432.CCR-13-0956  0.44
2013 Mistry H, Hsieh G, Buhrlage SJ, Huang M, Park E, Cuny GD, Galinsky I, Stone RM, Gray NS, D'Andrea AD, Parmar K. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Molecular Cancer Therapeutics. 12: 2651-62. PMID 24130053 DOI: 10.1158/1535-7163.MCT-13-0103-T  0.44
2013 O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, ... ... Stone RM, et al. Acute myeloid leukemia, version 2.2013. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 1047-55. PMID 24029121 DOI: 10.6004/JNCCN.2013.0127  0.44
2013 Glotzbecker BE, Yolin-Raley DS, DeAngelo DJ, Stone RM, Soiffer RJ, Alyea EP. Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical center Journal of Oncology Practice. 9. PMID 23943893 DOI: 10.1200/JOP.2012.000841  0.44
2013 Adamia S, Pilarski PM, Bar-Natan M, Stone RM, Griffin JD. Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target? Current Cancer Drug Targets. 13: 735-48. PMID 23906050  0.44
2013 Stroopinsky D, Rosenblatt J, Ito K, Mills H, Yin L, Rajabi H, Vasir B, Kufe T, Luptakova K, Arnason J, Nardella C, Levine JD, Joyce RM, Galinsky I, Reiter Y, ... Stone RM, et al. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Research. 73: 5569-79. PMID 23867470 DOI: 10.1158/0008-5472.CAN-13-0677  0.44
2013 Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, ... ... Stone RM, et al. Myelodysplastic syndromes: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 838-74. PMID 23847220  0.44
2013 Attar EC, Amrein PC, Fraser JW, Fathi AT, McAfee S, Wadleigh M, Deangelo DJ, Steensma DP, Stone RM, Foster J, Neuberg D, Ballen KK. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leukemia Research. 37: 1016-20. PMID 23773898 DOI: 10.1016/j.leukres.2013.05.011  0.44
2013 Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrózek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Powell BL, Carter TH, Wetzler M, ... ... Stone RM, et al. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia. 27: 2023-31. PMID 23765227 DOI: 10.1038/leu.2013.181  0.44
2013 Sherman AE, Motyckova G, Fega KR, Deangelo DJ, Abel GA, Steensma D, Wadleigh M, Stone RM, Driver JA. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leukemia Research. 37: 998-1003. PMID 23747082 DOI: 10.1016/j.leukres.2013.05.013  0.44
2013 Singh H, Lane AA, Correll M, Przychodzen B, Sykes DB, Stone RM, Ballen KK, Amrein PC, Maciejewski J, Attar EC. Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer Journal. 3: e117. PMID 23708642 DOI: 10.1038/bcj.2013.16  0.44
2013 Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Investigational New Drugs. 31: 1311-20. PMID 23700288 DOI: 10.1007/s10637-013-9978-z  0.44
2013 Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, ... ... Stone RM, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2086-93. PMID 23650424 DOI: 10.1200/JCO.2012.45.6228  0.44
2013 Leblebjian H, DeAngelo DJ, Skirvin JA, Stone RM, Wadleigh M, Werner L, Neuberg DS, Bartel S, McDonnell AM. Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leukemia Research. 37: 747-51. PMID 23643326 DOI: 10.1016/j.leukres.2013.04.011  0.44
2013 Stone RM. Consolidation chemotherapy for adults with AML in first remission: Is there a best choice? Journal of Clinical Oncology. 31: 2067-2069. PMID 23630213 DOI: 10.1200/JCO.2013.48.6886  0.44
2013 Stone RM. Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of Hematology Expert Review of Hematology. 6: 127-129. PMID 23547861 DOI: 10.1586/ehm.13.14  0.44
2013 Carnevale J, Ross L, Puissant A, Banerji V, Stone RM, DeAngelo DJ, Ross KN, Stegmaier K. SYK regulates mTOR signaling in AML. Leukemia. 27: 2118-28. PMID 23535559 DOI: 10.1038/leu.2013.89  0.44
2013 Stone RM. Acute myeloid leukemia in first remission: To choose transplantation or not? Journal of Clinical Oncology. 31: 1262-1266. PMID 23439752 DOI: 10.1200/JCO.2012.43.4258  0.44
2013 Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 923-9. PMID 23129738 DOI: 10.1200/JCO.2012.45.2177  0.44
2013 Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Mrózek K, Bloomfield CD, Larson RA. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 119: 90-8. PMID 22744771 DOI: 10.1002/cncr.27617  0.44
2013 Steensma DP, Stone RM. Myelodysplastic Syndromes Abeloff's Clinical Oncology: Fifth Edition. 1907-1928.e8. DOI: 10.1016/B978-1-4557-2865-7.00099-0  0.44
2012 Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais M, Griffin JD, Stone RM, Kung AL, Frank DA. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes & Cancer. 3: 503-11. PMID 23264850 DOI: 10.1177/1947601912466555  0.44
2012 Stone RM. Is it time to revisit standard post-remission therapy? Best Practice and Research: Clinical Haematology. 25: 437-441. PMID 23200540 DOI: 10.1016/j.beha.2012.10.006  0.44
2012 Brusic A, Hainz U, Wadleigh M, Neuberg D, Su M, Canning CM, Deangelo DJ, Stone RM, Lee JS, Mulligan RC, Ritz J, Dranoff G, Sasada T, Wu CJ. Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 1: 1095-1103. PMID 23170257 DOI: 10.4161/onci.20954  0.44
2012 Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, ... ... Stone RM, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 120: 4649-52. PMID 23074281 DOI: 10.1182/blood-2012-06-438267  0.44
2012 Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 151: 344-55. PMID 23063124 DOI: 10.1016/j.cell.2012.08.038  0.44
2012 Mrózek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu YZ, Kohlschmidt J, Pettenati MJ, Heerema NA, Block AW, Patil SR, Baer MR, ... ... Stone RM, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4515-23. PMID 22987078 DOI: 10.1200/JCO.2012.43.4738  0.44
2012 O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, ... ... Stone RM, et al. Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network : Jnccn. 10: 984-1021. PMID 22878824  0.44
2012 Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 26: 2061-8. PMID 22627678 DOI: 10.1038/leu.2012.115  0.44
2012 Banerji V, Frumm SM, Ross KN, Li LS, Schinzel AC, Hahn CK, Kakoza RM, Chow KT, Ross L, Alexe G, Tolliday N, Inguilizian H, Galinsky I, Stone RM, DeAngelo DJ, et al. The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. The Journal of Clinical Investigation. 122: 935-47. PMID 22326953 DOI: 10.1172/JCI46465  0.44
2012 Yang X, Liu S, Kharbanda S, Stone RM. AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD Leukemia Research. 36: 205-211. PMID 22142798 DOI: 10.1016/j.leukres.2011.09.006  0.44
2012 Wadleigh M, Rosenthal DS, Stone RM. Myelodysplasia Pathy's Principles and Practice of Geriatric Medicine: Fifth Edition. 1: 363-374. DOI: 10.1002/9781119952930.ch32  0.44
2011 Stone RM. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML? Best Practice and Research: Clinical Haematology. 24: 509-514. PMID 22127313 DOI: 10.1016/j.beha.2011.09.006  0.44
2011 Motyckova G, Stone RM. Treatment of elderly acute myeloid leukemia patients Current Treatment Options in Oncology. 12: 341-353. PMID 21901552 DOI: 10.1007/s11864-011-0162-4  0.44
2011 Poitras JL, Costa D, Kluk MJ, Amrein PC, Stone RM, Lee C, Dal Cin P, Morton CC. Genomic alterations in myeloid neoplasms with novel, apparently balanced translocations. Cancer Genetics. 204: 68-76. PMID 21504705 DOI: 10.1016/j.cancergen.2010.12.005  0.44
2011 O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, ... ... Stone RM, et al. Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 280-317. PMID 21393440 DOI: 10.6004/JNCCN.2011.0027  0.44
2011 Baer MR, George SL, Sanford BL, Mrózek K, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, Larson RA. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 25: 800-7. PMID 21321569 DOI: 10.1038/leu.2011.9  0.44
2011 Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, ... ... Stone RM, et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 30-56. PMID 21233243 DOI: 10.6004/JNCCN.2011.0005  0.44
2011 Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis Journal of Clinical Oncology. 29: 789-796. PMID 21220608 DOI: 10.1200/JCO.2010.32.8021  0.44
2011 Steensma DP, Stone RM. Lenalidomide in AML: Del(5q) or who? Blood. 118: 481-482. DOI: 10.1182/blood-2011-05-354324  0.44
2011 Motyckova G, Stone RM. Myeloproliferative Neoplasms and Myelodysplastic Syndromes Concise Guide to Hematology. 220-234. DOI: 10.1002/9781444345254.ch18  0.44
2010 Stone RM. New agents in post-remission therapy Best Practice and Research: Clinical Haematology. 23: 475-479. PMID 21130410 DOI: 10.1016/j.beha.2010.09.004  0.44
2010 Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 116: 3751-7. PMID 20705755 DOI: 10.1182/blood-2010-02-269621  0.44
2010 Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, ... ... Stone RM, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 116: 3622-6. PMID 20656931 DOI: 10.1182/blood-2010-05-283648  0.44
2010 Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A. CNS relapse in acute promyeloctyic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: e409-11. PMID 20530270 DOI: 10.1200/JCO.2009.27.1577  0.44
2010 Motyckova G, Stone RM. The role of molecular tests in acute myelogenous leukemia treatment decisions Current Hematologic Malignancy Reports. 5: 109-117. PMID 20425404 DOI: 10.1007/s11899-010-0049-7  0.44
2010 Steensma DP, Stone RM. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes Hematology/Oncology Clinics of North America. 24: 389-406. PMID 20359633 DOI: 10.1016/j.hoc.2010.02.012  0.44
2010 Abel GA, Van Bennekom CM, Stone RM, Anderson TE, Kaufman DW. Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients. Leukemia Research. 34: 939-41. PMID 20138359 DOI: 10.1016/j.leukres.2009.12.012  0.44
2010 Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, ... ... Stone RM, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 107: 252-7. PMID 20018760 DOI: 10.1073/pnas.0911726107  0.44
2010 Wadleigh M, Stone RM. Management of chronic leukemia in older adults Practical Geriatric Oncology. 230-244. DOI: 10.1017/CBO9780511763182.016  0.44
2009 Greenberg PL, Rigsby CK, Stone RM, Deeg HJ, Gore SD, Millenson MM, Nimer SD, O'Donnell MR, Shami PJ, Kumar R. NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network : Jnccn. 7: S1-16. PMID 20064286  0.44
2009 Stone RM. Prognostic factors in AML in relation to (ab)normal karyotype Best Practice and Research: Clinical Haematology. 22: 523-528. PMID 19959103 DOI: 10.1016/j.beha.2009.07.003  0.44
2009 Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC, Ross L, Galinsky I, Davis TN, Silver SJ, Root DE, Stone RM, DeAngelo DJ, Carroll M, Hahn WC, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 16: 281-94. PMID 19800574 DOI: 10.1016/j.ccr.2009.08.018  0.44
2009 Rhodes J, Amsterdam A, Sanda T, Moreau LA, McKenna K, Heinrichs S, Ganem NJ, Ho KW, Neuberg DS, Johnston A, Ahn Y, Kutok JL, Hromas R, Wray J, Lee C, ... ... Stone RM, et al. Emi1 maintains genomic integrity during zebrafish embryogenesis and cooperates with p53 in tumor suppression. Molecular and Cellular Biology. 29: 5911-22. PMID 19704007 DOI: 10.1128/MCB.00558-09  0.44
2009 Tefferi A, Stone RM. Iron chelation therapy in myelodysplastic syndrome - Cui bono? Leukemia. 23: 1373. PMID 19672273 DOI: 10.1038/leu.2009.39  0.44
2009 Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. Jama. 301: 2349-61. PMID 19509382 DOI: 10.1001/jama.2009.813  0.36
2009 Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, ... ... Stone RM, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3472-9. PMID 19487385 DOI: 10.1200/JCO.2007.14.3339  0.44
2009 Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, ... ... Stone RM, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 114: 144-7. PMID 19420352 DOI: 10.1182/blood-2009-03-210039  0.44
2009 Stone RM. How I treat patients with myelodysplastic syndromes Blood. 113: 6296-6303. PMID 19383969 DOI: 10.1182/blood-2008-09-038935  0.44
2009 Corsello SM, Roti G, Ross KN, Chow KT, Galinsky I, DeAngelo DJ, Stone RM, Kung AL, Golub TR, Stegmaier K. Identification of AML1-ETO modulators by chemical genomics. Blood. 113: 6193-205. PMID 19377049 DOI: 10.1182/blood-2008-07-166090  0.44
2009 Wadleigh M, Stone RM. The role of myeloid growth factors in acute leukemia Jnccn Journal of the National Comprehensive Cancer Network. 7: 84-91. PMID 19176208  0.44
2009 Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, Deangelo DJ, Marcucci G, Bloomfield CD, Larson RA. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemotherapy and Pharmacology. 63: 859-64. PMID 18670778 DOI: 10.1007/s00280-008-0805-8  0.44
2009 Stone RM, DeAngelo DJ. Screens, iron, and leukemia Blood. 114: 2857-2858. DOI: 10.1182/blood-2009-08-234161  0.44
2009 Alexander W, Stone RM. American Society of Clinical Oncology, 45th Annual Meeting - Dasatinib (Sprycel) for chronic-phase chronic myeloid leukemia (three-year follow-up) P and T. 34: 380.  0.44
2008 el-Shami K, Stone RM, Smith BD. FLT3 inhibitors in acute myeloid leukemia Expert Review of Hematology. 1: 153-160. PMID 21082920  0.44
2008 DeAngelo DJ, Stone RM. New agents for the treatment of patients with acute lymphoblastic leukemia Current Hematologic Malignancy Reports. 3: 135-143. PMID 20425458 DOI: 10.1007/s11899-008-0020-z  0.44
2008 Sirulnik LA, Stone RM. Lenalidomide in myelodysplastic syndromes: Where do we go from here? Current Hematologic Malignancy Reports. 3: 5-9. PMID 20425440 DOI: 10.1007/s11899-008-0002-1  0.44
2008 Stone RM. Are new agents really making a difference in MDS? Best Practice and Research: Clinical Haematology. 21: 639-646. PMID 19041603 DOI: 10.1016/j.beha.2008.06.004  0.44
2008 Stone RM, DeAngelo DJ, Janosova A, Galinsky I, Canning C, Ritz J, Soiffer RJ. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission American Journal of Hematology. 83: 771-777. PMID 18756547 DOI: 10.1002/ajh.21253  0.44
2008 Kesari S, Drappatz J, Akar S, Vergilio JA, Wen PY, Soiffer RJ, Stone RM, Deangelo DJ. Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass Journal of Clinical Oncology. 26: 3279-3281. PMID 18591563 DOI: 10.1200/JCO.2007.15.6729  0.44
2008 Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrózek K, Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, Larson RA. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4934-9. PMID 18591543 DOI: 10.1200/JCO.2008.17.0472  0.44
2008 Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. Leukemia & Lymphoma. 49: 1274-8. PMID 18452072 DOI: 10.1080/10428190802043887  0.44
2008 Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, ... Stone RM, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1446-54. PMID 18316568 DOI: 10.1158/1078-0432.CCR-07-4626  0.44
2008 Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J, Tanguturi S, Ladd-Acosta C, Stone R, Golub TR, Raza A. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. Plos Medicine. 5: e35. PMID 18271621 DOI: 10.1371/journal.pmed.0050035  0.44
2008 Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 111: 4788-96. PMID 18252861 DOI: 10.1182/blood-2007-07-101394  0.44
2008 Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Gambacorti C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 111: 1039-43. PMID 17932248 DOI: 10.1182/blood-2007-07-103523  0.44
2008 Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 111: 86-93. PMID 17893227 DOI: 10.1182/blood-2007-01-068833  0.44
2008 Alexander W, Stone RM. American Society of Clinical Oncology: Dasatinib (Sprycel) in chronic myelogenous leukemia P and T. 33: 399-400.  0.44
2007 Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Döhner H, Döhner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, ... ... Stone RM, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 12: 501-13. PMID 18068628 DOI: 10.1016/j.ccr.2007.11.005  0.44
2007 Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM, Ritz J, Alyea EP, Antin JH, Soiffer RJ. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 655-64. PMID 17531775 DOI: 10.1016/j.bbmt.2007.01.079  0.44
2007 Stone RM. Novel therapeutic agents in acute myeloid leukemia Experimental Hematology. 35: 163-166. PMID 17379102 DOI: 10.1016/j.exphem.2007.01.025  0.44
2007 Stone RM. Targeted agents in AML: much more to do Best Practice and Research: Clinical Haematology. 20: 39-48. PMID 17336253 DOI: 10.1016/j.beha.2006.11.006  0.44
2007 Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, Hsu K, Bloomfield CD, Stone RM, DeAngelo DJ, Galinsky IA, Issa JP, Clarke MF, Look AT. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nature Medicine. 13: 78-83. PMID 17159988 DOI: 10.1038/nm1512  0.44
2007 Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 109: 2303-9. PMID 17138817 DOI: 10.1182/blood-2006-09-047266  0.44
2006 Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine. 355: 2408-17. PMID 17151364 DOI: 10.1056/NEJMoa062867  0.44
2006 DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 108: 3674-81. PMID 16902153 DOI: 10.1182/blood-2006-02-005702  0.44
2006 Larson RA, Stone RM, Mayer RJ, Schiffer CA. Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3556s-63s. PMID 16740785 DOI: 10.1158/1078-0432.CCR-06-9001  0.44
2006 Stone RM. Is intravenous arsenic trioxide a useful therapy in myelodysplastic syndromes? Journal of Clinical Oncology. 24: 2414-2416. PMID 16651644 DOI: 10.1200/JCO.2005.05.4759  0.44
2006 Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 108: 419-25. PMID 16609072 DOI: 10.1182/blood-2005-10-4149  0.44
2006 Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, Bloomfield CD. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. International Journal of Oncology. 28: 1099-103. PMID 16596225  0.44
2006 Farag SS, Archer KJ, Mrózek K, Ruppert AS, Carroll AJ, Vardiman JW, Pettenati MJ, Baer MR, Qumsiyeh MB, Koduru PR, Ning Y, Mayer RJ, Stone RM, Larson RA, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 108: 63-73. PMID 16522815 DOI: 10.1182/blood-2005-11-4354  0.44
2006 Stone RM. Older AML patients: Fit for what? Blood. 108: 3232-3233. DOI: 10.1182/blood-2006-09-042960  0.44
2006 Chang AE, Hayes DF, Pass HI, Stone RM, Ganz PA, Kinsella TJ, Schiller JH, Strecher VJ. Oncology: An evidence-based approach Oncology: An Evidence-Based Approach. 1-2005. DOI: 10.1007/0-387-31056-8  0.44
2005 Sirulnik LA, Stone RM. Acute promyelocytic leukemia: Current strategies for the treatment of newly diagnosed disease Clinical Advances in Hematology and Oncology. 3. PMID 16167012  0.44
2005 Haining WN, Cardoso AA, Keczkemethy HL, Fleming M, Neuberg D, DeAngelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler LM, Guinan EC. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Experimental Hematology. 33: 286-94. PMID 15730852 DOI: 10.1016/j.exphem.2004.12.001  0.44
2005 Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood. 105: 22-30. PMID 15358622 DOI: 10.1182/blood-2003-11-3896  0.44
2005 Stone RM, Cortes JE. Farnesyl transferase inhibitors in myeloid disorders: Commentary Oncology. 19.  0.44
2004 Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Galinsky I, Huntly B, Cohen PS, Meyer T, ... ... Stone RM, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America. 101: 14479-84. PMID 15448205 DOI: 10.1073/pnas.0404438101  0.44
2004 Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, et al. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 104: 1855-8. PMID 15178581 DOI: 10.1182/blood-2004-02-0712  0.44
2004 Stone RM, Gilliland DG, Klion AD. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome Seminars in Oncology. 31: 12-17. PMID 15175999 DOI: 10.1053/j.seminoncol.2004.03.035  0.44
2004 Stone RM. Optimizing treatment of chronic myeloid leukemia: A rational approach Oncologist. 9: 259-270. PMID 15169981 DOI: 10.1634/theoncologist.9-3-259  0.44
2004 Sekeres MA, Peterson B, Dodge RK, Mayer RJ, Moore JO, Lee EJ, Kolitz J, Baer MR, Schiffer CA, Carroll AJ, Vardiman JW, Davey FR, Bloomfield CD, Larson RA, Stone RM, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 103: 4036-42. PMID 14976037 DOI: 10.1182/blood-2003-09-3118  0.44
2003 Lin NU, Sarantopoulos S, Stone JR, Galinsky I, Stone RM, Deangelo DJ, Soiffer RJ. Fatal hepatic necrosis following imatinib mesylate therapy [1] Blood. 102: 3455-3456. PMID 14568907 DOI: 10.1182/blood-2003-07-2323  0.44
2003 Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, Coutre SE, Stone RM, DeAngelo DJ, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell. 3: 459-69. PMID 12781364 DOI: 10.1016/S1535-6108(03)00108-9  0.44
2003 Stone RM. Induction and postremission therapy: New agents Leukemia. 17: 496-498. PMID 12646937 DOI: 10.1038/sj.leu.2402864  0.44
2003 Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, Stewart CC, Hurd DD, Kolitz JE, Velez-Garcia E, Stone RM, Bloomfield CD, Schiffer CA, Larson RA. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer. 97: 1471-80. PMID 12627512 DOI: 10.1002/cncr.11219  0.44
2003 Roufosse FE, Goldman M, Cogan E, Gilliland DG, Stone RM, Coutre SE. Hypereosinophilic syndrome [2] (multiple letters) New England Journal of Medicine. 348: 2687. DOI: 10.1056/NEJM200306263482616  0.44
2002 Stone RM. The difficult problem of acute myeloid leukemia in the older adults Ca-a Cancer Journal For Clinicians. 52: 363-371. PMID 12469764  0.44
2002 Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM, Friedberg J, DeAngelo D, Liney D, Windawi S, Ng A, Mauch P, Antin JH, et al. Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 8: 601-7. PMID 12463479 DOI: 10.1053/BBMT.2002.V8.ABBMT080601  0.44
2002 Stone RM. Treatment of acute myeloid leukemia: State-of-the-art and future directions Seminars in Hematology. 39: 4-10. PMID 12214287  0.44
2002 Stone RM. New therapies in leukemia: Renewed hope Journal of Hematotherapy and Stem Cell Research. 11: 583-587. PMID 12201947 DOI: 10.1089/15258160260194730  0.44
2002 Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2429-40. PMID 12011120 DOI: 10.1200/JCO.2002.04.117  0.44
2002 Sekeres MA, Stone RM. The challenge of acute myeloid leukemia in older patients Current Opinion in Oncology. 14: 24-30. PMID 11790976 DOI: 10.1097/00001622-200201000-00005  0.44
2002 Huang SS, Chan IT, Stone RM, Baden LR. Successful treatment of angioinvasive aspergillosis during prolonged neutropenia with liposomal amphotericin, voriconazole, and caspofungin Infectious Diseases in Clinical Practice. 11: 355-358. DOI: 10.1097/01.idc.0000078754.71576.ce  0.44
2001 Stone RM. Postremission therapy in adults with acute myeloid leukemia Seminars in Hematology. 38: 17-23. PMID 11474493  0.44
2001 Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, Lee EJ, Moore JO, Powell BL, Baer MR, Bloomfield CD, Schiffer CA. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 98: 548-53. PMID 11468148 DOI: 10.1182/blood.V98.3.548  0.44
2001 Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 1152-9. PMID 11181681 DOI: 10.1200/JCO.2001.19.4.1152  0.44
2000 Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia Blood. 95: 2530-2535. PMID 10753831  0.44
1998 Stone RM. Overview of randomized trials of growth factors in acute myeloid leukemia Leukemia and Lymphoma. 30: 38-40.  0.44
1997 Still IH, Chernova O, Hurd D, Stone RM, Cowell JK. Molecular characterization of the t(8; 13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: Evidence for three discrete loci involved in myeloid leukemias on 8p11 Blood. 90: 3136-3141. PMID 9376595  0.44
1996 Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfield CD. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 14: 2486-94. PMID 8823327  0.44
1995 Inhorn RC, Aster JC, Roach SA, Slapak CA, Soiffer R, Tantravahi R, Stone RM. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8; 13)(p11;q11): Description of a distinctive clinicopathologic entity Blood. 85: 1881-1887. PMID 7661940  0.44
1994 Yang KD, Mizobuchi T, Kharbanda SM, Datta R, Huberman E, Kufe DW, Stone RM. All-trans retinoic acid reverses phorbol ester resistance in a human myeloid leukemia cell line. Blood. 83: 490-6. PMID 8286746  0.44
1994 Stone RM. Myelodysplastic syndrome after autologous transplantation for lymphoma: The price of progress? Blood. 83: 3437-3440. PMID 8204870  0.44
1994 Yang KD, Shaio MF, Wang CL, Wu NC, Stone RM. Neuroblastoma cell-mediated leukocyte chemotaxis: lineage-specific differentiation of interleukin-8 expression. Experimental Cell Research. 211: 1-5. PMID 8125147 DOI: 10.1006/excr.1994.1050  0.44
1994 Stone RM, Bernstein SH, Demetri G, Facklam DP, Arthur K, Andersen J, Aster JC, Kufe D. Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes Leukemia Research. 18: 769-776. PMID 7934135 DOI: 10.1016/0145-2126(94)90059-0  0.44
1994 Robertson MJ, Roy DC, Stone RM, Ritz J. Use of CD33 monoclonal antibodies in bone marrow transplantation for acute myeloid leukemia Progress in Clinical and Biological Research. 389: 47-63. PMID 7700916  0.44
1993 Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW. Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. American Journal of Clinical Oncology. 16: 159-63. PMID 8452111  0.44
1993 Stone RM, Mayer RJ. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematology/Oncology Clinics of North America. 7: 47-64. PMID 8449864  0.44
1993 Hsu HC, Yang K, Kharbanda S, Clinton S, Datta R, Stone RM. All-trans retinoic acid induces monocyte growth factor receptor (c-fms) gene expression in HL-60 leukemia cells. Leukemia. 7: 458-62. PMID 8445950  0.44
1993 Stone RM, Mayer RJ. The approach to the elderly patient with acute myeloid leukemia. Hematology/Oncology Clinics of North America. 7: 65-79. PMID 7680642  0.44
1992 Stone RM. Hematopoietic growth factors and leukemia Current Opinion in Oncology. 4: 33-44. PMID 1591293  0.44
1992 Rubin EH, Andersen JW, Berg DT, Schiffer CA, Mayer RJ, Stone RM. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 10: 948-53. PMID 1588374  0.44
1992 Eng C, Farraye FA, Shulman LN, Peppercorn MA, Krauss CM, Connors JM, Stone RM. The association between the myelodysplastic syndromes and crohn disease Annals of Internal Medicine. 117: 661-662. PMID 1530197  0.44
1992 Yang KD, Stone RM, Lee CS, Chao TY, Cheng SN, Shaio MF. Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: Implication of monocyte-derived neutrophil-activating factors Cancer Immunology Immunotherapy. 35: 277-282. PMID 1511463 DOI: 10.1007/BF01789335  0.44
1992 Schiffer CA, Stone RM, Peterson BA, Moore J. CALGB studies with hematopoietic growth factors in patients with AML Leukemia and Lymphoma. 7: 65. DOI: 10.3109/10428199209058664  0.44
1991 Datta R, Sherman ML, Stone RM, Kufe D. Expression of the jun-B gene during induction of monocytic differentiation. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 2: 43-9. PMID 2007095  0.44
1991 Bernstein SH, Kharbanda SM, Sherman ML, Stone RM, Kufe DW. Inhibition of protein kinase C is associated with a decrease in c-myc expression in human myeloid leukemia cells Febs Letters. 294: 73-76. PMID 1743296 DOI: 10.1016/0014-5793(91)81346-A  0.44
1990 Stone RM, Spriggs DR, Dhawan RK, Arthur KA, Mayer RJ, Kufe DW. A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia Leukemia. 4: 843-847. PMID 2243507  0.44
1990 Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia Journal of Clinical Oncology. 8: 1913-1921. PMID 2230879  0.44
1990 Stone RM, Imamura K, Datta R, Sherman ML, Kufe DW. Inhibition of phorbol ester-induced monocytic differentiation and c-fms gene expression by dexamethasone: potential involvement of arachidonic acid metabolites. Blood. 76: 1225-32. PMID 2144778  0.44
1990 Sherman ML, Stone RM, Datta R, Bernstein SH, Kufe DW. Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. The Journal of Biological Chemistry. 265: 3320-3. PMID 2105946  0.44
1988 Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: Experience in 34 patients Blood. 71: 690-696. PMID 3422828  0.44
1988 Stone RM, Weber BL, Spriggs DR, Kufe DW. Phospholipase C activates protein kinase C and induces monocytic differentiation of HL-60 cells Blood. 72: 739-744. PMID 3165300  0.44
1988 Stone RM, Sariban E, Pettit GR, Kufe DW. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells Blood. 72: 208-213. PMID 2455568  0.44
1987 Goldberg MA, Ginsburg D, Mayer RJ, Stone RM, Maguire M, Rosenthal DS, Antin JH. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood. 69: 187-191. PMID 3466655  0.44
1986 Spriggs DR, Stone RM, Kufe DW. The treatment of myelodysplastic syndromes Clinics in Haematology. 15: 1081-1107. PMID 3552348  0.44
Show low-probability matches.